Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing
BOSTON and EDISON, N.J., July 15 /PRNewswire/ -- A sub-analysis of a Phase IIb multinational study(1) with edoxaban(2) - an investigational oral Factor Xa inhibitor - provides insights into why patients with non-valvular atrial fibrillation (AF) receiving edoxaban once daily (QD) experie...
CRESTOR(R) Reduced CV Risk in Patients Achieving Low LDL and hsCRP Targets in New JUPITER Analysis
ORLANDO, Fla., March 29 /PRNewswire-FirstCall/ -- Results from a new sub-
analysis of the JUPITER study show that patients with low to normal
cholesterol levels and elevated high sensitivity C-reactive protein (hsCRP)
who attained a dual treatment target of LDL-C <70mg/dL and hsCRP <2mg/...
CRESTOR(R) Reduced Risk of Blood Clots in the Veins
ORLANDO, Fla., March 29 /PRNewswire-FirstCall/ -- A new analysis from the
JUPITER study shows that CRESTOR(R) (rosuvastatin calcium) 20mg significantly
cut the risk of venous thromboembolism (VTE) by 43% (p =0.007) compared to
placebo among men and women with low to normal cholesterol levels a...
Cymbalta(R) Significantly Reduced Osteoarthritis Knee Pain in New Study
INDIANAPOLIS, Jan. 30 /PRNewswire-FirstCall/ -- In a new study, Cymbalta
(duloxetine HCl) 60-120 mg, taken once daily, reduced
significantly, compared with placebo, in patients with osteoarthritis pain of
the knee. Data from the 13-week randomized, double-blind, placebo-controlle...
Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome
- Results Presented at ASH Annual Meeting-
SAN FRANCISCO, Dec. 6 /PRNewswire-FirstCall/ -- Sanofi-aventis today announced results of a randomized phase III study presented at the 50th Annual Meeting of the American Society of Hematology. The study in adult patients with hematological mali...
GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP
PHILADELPHIA, Dec. 6 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK )
announced positive safety and efficacy results from RAISE (RAndomized placebo-
controlled ITP Study with Eltrombopag), a Phase III study of PROMACTA(R)
(eltrombopag) in adults with chronic immune (idiopathic) thrombocyto...
Dronedarone (Multaq(R)) Reduced the Incidence and Duration of Hospitalization in Patients with Atrial Fibrillation
New post-hoc analysis from ATHENA Study showed that Multaq(R) on top of
standard therapy significantly decreased the total number of hospital days
by 28% in patients with atrial fibrillation or flutter
NEW ORLEANS, Nov. 11 /PRNewswire-FirstCall/ -- New data from the
landmark ATHENA trial sho...
Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity in Patients With Lupus
Encouraging Clinical Data Presented at American College of Rheumatology
(ACR) meeting Show Reduced
Need for Concomitant Corticosteroid Therapy
SAN FRANCISCO, Oct. 27 /PRNewswire-FirstCall/ -- UCB (Euronext
Brussels: UCB) announced data from two randomized controlled trials showing
ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments
- Results of two Phase III studies affirmed the clinical benefits of
NUTLEY, N.J., Oct. 25 /PRNewswire/ -- Data from two Phase III studies
showed that patients who suffer from the debilitating and painful effects
of rheumatoid arthritis (RA) achieved significant improvements in sig...
Spherics, Inc. Announces Reduced Cognitive Impairment of Novel Extended Release Topiramate (SRx-502) as Compared to Topamax(R)
Findings Presented At The American Society Of Clinical Psychopharmacology Meeting
WELLESLEY HILLS, Mass., Sept. 15 /PRNewswire/ -- Joseph F. Finn, Jr.,
C.P.A. ("Finn"), Assignee of the assets of Spherics, Inc. ("Spherics") for
the benefit of creditors, announced t...
New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients
-Data Published in 'The Lancet' and Presented at ESC Congress-
PHILADELPHIA, Sept. 4 /PRNewswire/ -- Results from a new international
study, the GISSI Heart Failure (GISSI-HF) study, showed that 1 g/d dose of
omega-3 acid ethyl esters reduced
all cause mortality and hospital
Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
This analysis showed that Multaq(R) (dronedarone) decreased the risk of
stroke by 34% in patient with atrial fibrillation or atrial flutter already adequately treated by antithrombotic therapy
BRIDGEWATER, N.J., Sept. 3 /PRNewswire-FirstCall/ -- The results of a
post-hoc analysis ...
Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel
MUNICH, Germany, Sept. 3 /PRNewswire-FirstCall/ -- A sub-analysis of
the TRITON-TIMI 38 clinical trial showed that treatment with prasugrel
compared with clopidogrel significantly reduced
the risk of new or
recurrent heart attacks (7.4 percent vs. 9.7 percent, p<0.0001), regardless
of whether ...
Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
PARIS, September 3 /PRNewswire-FirstCall/ --
- This Analysis Showed That Multaq(R) (Dronedarone) Decreased the Risk
of Stroke by 34% in Patients With Atrial Fibrillation or Atrial Flutter
Already Adequately Treated by Antithrombotic Therapy
The results of a post-hoc analysis of the data fr...
Catheter Ablation System for Atrial Fibrillation Shows Reduced Procedure Time, Remarkable Safety Profile and Excellent Outcomes in Two Clinical Studies
Important Studies Presented at the European Society of Cardiology Continue to Bring Attention to Innovative Technology
CARLSBAD, Calif., Sept. 2 /PRNewswire/ -- Ablation Frontiers, Inc.,
announced today that two important studies, involving its innovative atrial
Prasugrel Head-to-Head Study Showed Reduced Cardiovascular Events in Diabetes Patients by 30 Percent Compared with Clopidogrel
Sub-group analysis of landmark trial showed prasugrel substantially reduced
risk of heart attack and stent thrombosis compared with clopidogrel among ACS patients with diabetes
MUNICH, Germany, Aug. 31 /PRNewswire-FirstCall/ -- Patients who were
diabetic and diagnosed with...
Bad News to Bad Bugs: Northern Antibiotics Develops Novel Polymyxins With Reduced Toxicity
HELSINKI, July 1 /PRNewswire/ -- The emergence of multidrug-resistant
Gram-negative bacteria has necessitated the use of polymyxins as the agents
of last resort despite their known nephrotoxicity. Now Northern Antibiotics
Ltd, a Finnish biotech company, has developed novel polymyxin derivative...
Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study
Patients on Treatment Also Experienced Improved Physical Functioning
INDIANAPOLIS, June 13 /PRNewswire-FirstCall/ -- New data suggest that
patients with osteoarthritis pain of the knee treated with 60 mg and 120 mg
Cymbalta (duloxetine HCl) once daily experienced significant pain
Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes
Phase 3 data highlight sustained efficacy and benefits of early treatment with liraglutide versus glimepiride
SAN FRANCISCO, June 9 /PRNewswire-FirstCall/ -- Data presented today at
the 68th Scientific Sessions of the American Diabetes Association (ADA)
demonstrated that once-d...
CellCept(R) and a Reduced Level of CNI Shows Trend Towards Preservation of Kidney Function Versus a Standard-Dose CNI
TORONTO, June 4 /PRNewswire/ -- The 12-month results from a multicenter
trial monitoring CellCept(R) (mycophenolate mofetil) in combination with
calcineurin inhibitors (CNIs) in renal transplantation was presented today
at the American Transplant Congress (ATC). The study results showed that a...
Data Show Rufinamide, an Investigational Adjunctive Treatment for Lennox- Gastaut Syndrome, Reduced Drop Attacks by More Than 40%
Placebo-Controlled Study Results Published in May 20 Issue of Neurology
WOODCLIFF LAKE, N.J., May 20 /PRNewswire/ -- Eisai Corporation of North
America announced today the publication of a placebo-controlled study in
Neurology that found patients with Lennox-Gastaut syndrome (LGS) treated
Pivotal Study Shows Physician/Nurse Teams Using SEDASYS(TM) System Reduced Risk of Over Sedation With Propofol
SAN DIEGO, May 19 /PRNewswire/ -- DDW 2008 Annual Meeting -- Ethicon
Endo-Surgery announced today that the results from its pivotal trial
demonstrated physician/nurse teams using the SEDASYS(TM) System reduced
risk of over sedation with propofol in patients undergoing screening and
Data Presented at AAN Show That Lacosamide Significantly Reduced Pain and was Generally Well Tolerated in Patients With Diabetic Neuropathic Pain
UCB announces clinical data presented at the 60th Annual Meeting of the American Academy of Neurology (AAN) in Chicago
SMYRNA, Ga., April 16 /PRNewswire/ -- UCB presented efficacy and safety
results from pooled analyses of Phase II and III double-blind, randomized,
Medivation's Dimebon(TM) Significantly Improved Daily Function in Alzheimer's Disease Patients, Resulting in Reduced Need for Caregiver Assistance
- Activities of Daily Living Data from Pivotal Trial Presented at American Academy of Neurology 60th Annual Meeting -
SAN FRANCISCO and CHICAGO, April 15 /PRNewswire-FirstCall/ --
Medivation, Inc. (Nasdaq: MDVN ) today announced that Alzheimer's patients
taking the investigationa...
Lotrel, a Single-Pill Combination for Treating High Blood Pressure, Reduced Cardiovascular Events by 20% in High-Risk Patients
- ACCOMPLISH first study to compare two single-pill combinations of
commonly used high blood pressure medicines in reduction of cardiovascular events - RAS inhibition with an ACEI was the foundation of the combination
therapies in this study and exceptional b...
Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases
- EPOC Results Published in March 22 Issue of The Lancet -
BRIDGEWATER, N.J., March 20 /PRNewswire-FirstCall/ -- Sanofi-aventis
today announced that efficacy results of the randomized phase III EORTC
40983 Intergroup study published in the March 22 issue of The Lancet showed
that in eli...
Medivation's Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimer's Disease Patients, Resulting in Reduced Caregiver Distress
-- Neuropsychiatric Data from Pivotal Trial Presented at Annual Meeting of American Association for Geriatric Psychiatry --
SAN FRANCISCO and ORLANDO, Fla., March 15 /PRNewswire-FirstCall/ --
Medivation, Inc. (Nasdaq: MDVN ) today announced that clinical results from
its first pivot...
Breast Cancer Treatment Is Reduced to One Week
Chicago-Area Community Hospital to Offer New Clinical Study to Breast Cancer Patients
EVERGREEN PARK, Ill., Jan. 29 /PRNewswire/ -- Little Company of Mary
Hospital and Health Care Centers in Evergreen Park, Illinois, near Chicago
Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH)
-Patients treated with Lovenox(R) (enoxaparin sodium injection) were also less likely to be readmitted to hospital within 90 days-
BRIDGEWATER, N.J., Dec 10 /PRNewswire-FirstCall/ -- Sanofi-aventis
announced today the results of a study that demonstrated total hospital
direct medical cos...
LAP-BAND(R) System Weight-Loss Surgery Associated With More Than 70 Percent Reduced Risk of Death in People With Severe Obesity
Observational study published in the Annals of Surgery
MELBOURNE, Australia, Nov. 21 /PRNewswire/ -- Severely obese people who
received the LAP-BAND(R) Adjustable Gastric Banding System to lose weight
had a 72 percent reduction in their risk of dying compared to obese people
who were ...
New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
Patients with Painful and Progressive Form of Inflammatory Spinal Arthritis Receiving Monthly Golimumab Treatment Showed Marked Improvements in Physical Function
BOSTON, Nov. 7 /PRNewswire/ -- More than half of patients receiving
monthly subcutaneous (SC) injections of...
Tezampanel, TorreyPines Therapeutics' Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
Data Suggest Potential for Treating Motor System Disorders
LA JOLLA, Calif., Oct. 17 /PRNewswire/-- Tezampanel, a novel small
molecule currently in clinical development by TorreyPines Therapeutics,
Inc. (Nasdaq: TPTX ) for the treatment of acute migraine headache, was shown
in an indep...
New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
Investigational Extended-Release Formulation Reduced
Seizures in Patients Who Were Inadequately Controlled
RESEARCH TRIANGLE PARK, N.C., Oct. 15 /PRNewswire-FirstCall/ -- New
recently published data show that Lamictal(R)XR(TM) (lamotrigine) Extended-
Release Tablets significa...
INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
ORLANDO, Fla., Oct. 13 /PRNewswire/ -- Acutely ill, hospitalized
patients with schizophrenia showed significant improvement in symptoms
after taking INVEGA(TM) (paliperidone) Extended-Release Tablets as compared
to SEROQUEL(R)(a) (quetiapine) and placebo. Symptom improvement was
observed with ...
ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
Results presented at the 43rd European Association for the Study of Diabetes Annual Meeting
AMSTERDAM, The Netherlands, Sept. 19 /PRNewswire/ -- Results presented
today at the 43rd Annual Meeting of the European Association for the Study
of Diabetes demonstrate the abi...
Risedronate Reduced Risk of Fracture Among Osteoporotic Postmenopausal Women with History of Hip Fracture
HONOLULU, Sept. 17 /PRNewswire-FirstCall/ -- In a new analysis reported
at the American Society for Bone and Mineral Research (ASBMR) 29th Annual
Meeting, risedronate 5 mg decreased clinical fracture risk by 50% over
three years relative to placebo in a group of postmenopausal women with
MedImmune's Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
GAITHERSBURG, Md., Aug. 23 /PRNewswire/ -- MedImmune, Inc. today
announced that in a Phase 3 study, motavizumab was shown to reduce
hospitalizations due to respiratory syncytial virus (RSV) by 83 percent as
compared to placebo (8.3 percent in placebo arm vs. 1.4 percent in
New Data Suggest Cymbalta(R) Reduced Pain in Fibromyalgia Patients With and Without Depression
INDIANAPOLIS, Aug. 21 /PRNewswire-FirstCall/ -- New data suggest that
patients with fibromyalgia treated with 60mg or 120mg of Cymbalta(R)
(duloxetine HCl) experienced greater reduction in pain severity beginning
one week after starting duloxetine than those taking placebo (sugar pill),
In New Study, Duloxetine Reduced Non-specific Pain and Emotional
Symptoms Associated with Depression
MADRID, Spain, 19 march 2007 - The antidepressant duloxetine, at
a once-daily dose of 60 mg, significantly reduced
and emotional symptoms associated with depression in a new,
eight-week, placebo-controlled study of 327 adult patients with at
least moderate pain and major depressi...
Lyrica Significantly Reduced Pain and Helped Patients Manage the
Symptoms of Fibromyalgia, Data Show
BOSTON--(BUSINESS WIRE)--May 1, 2007 - Significantly more patients
treated with Pfizer's Lyrica reduced
their pain by 50 percent or
more compared with placebo, according to study results presented
today at the American Academy of Neurology annual meeting.
Clinically, this outcome would equate to a ...